Trending: Quantum computing is coming: Here’s why Seattle needs to get our computer science workforce ready

vesifloMedical device maker Vesiflo has secured $650,000 in funding ahead of its commercial launch later this year.

The Redmond-based company, which makes a device that replaces traditional urinary catheters, may raise up to $2 million as part of its first round. Vesiflo’s Chief Business Officer Susan Robinson confirmed the funding, which was originally disclosed in a document filed with the Securities & Exchange Commission.

Robinson declined to provide other details, such as a list of investors.

Vesiflo’s product is a pump designed for women, who can no longer urinate spontaneously due to a medical condition, which is often the consequent of a stroke, Parkinson’s or diabetes. Vesiflo received clearance from the FDA to market its inFlow Urinary Prosthesis in October 2014, and plans to launch the product commercially this year.

Vesiflo management team has a strong track record of starting and running large biotech companies.

The company’s President and CEO Kevin Connolly previously founded Massachusetts-based SRS Medical, which is now owned by Schooner Capital. Prior to that, he was Founder and CEO of Davicon, a manufacturer of medical instruments that he also sold to a group of private investors.

Robinson’s name may also sound familiar. Previously, she was the CEO of Targeted Genetics, a struggling Seattle biotech company that was spun off from Immunex in 1989 and then bought by Genzyme for $7 million in 2009.

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline


Job Listings on GeekWork

Help Desk ManagerHuman Rights Campaign
Web DeveloperRad Power Bikes
UX DesignerTINYpulse
Find more jobs on GeekWork. Employers, post a job here.